CASE REPORT article
Front. Med.
Sec. Nephrology
This article is part of the Research TopicChallenge to the Future: Advances in post-COVID-19 intensive care NephrologyView all 5 articles
CytoSorb Hemoadsorption as an Adjunctive Therapy in Critically Ill Pregnant Women with COVID-19 and Acute Kidney Injury: A Case Series
Provisionally accepted
Minoo Heidari AlmasiMir Mohammad MiriKiana EntezarmahdiTahereh SabaghianSoheila Sadeghi
Amirahmad Nassiri*- Shahid Beheshti University of Medical Sciences, Tehran, Tehran, Iran
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Purpose: Critically ill pregnant women with COVID-19 are at high risk for acute kidney injury (AKI) and a hyperinflammatory state, contributing to multiorgan failure. This case series describes the adjunctive use of CytoSorb hemoadsorption therapy in this population. Methods: We present four critically ill pregnant women with COVID-19 pneumonia, AKI, and clinical signs of hyperinflammation. All patients were admitted to the intensive care unit (ICU) and received CytoSorb therapy, integrated with continuous renal replacement therapy (CRRT) or used as a standalone treatment. We analyzed clinical parameters (SOFA score, vasopressor requirement, PaO₂/FiO₂ ratio) and inflammatory biomarkers (C-reactive protein, ferritin) before and after CytoSorb initiation. Results: Following CytoSorb therapy, all four patients showed clinical improvement, evidenced by a reduction in SOFA scores, decreased vasopressor needs, and improved oxygenation. A concomitant decrease in inflammatory markers was also observed. All four patients survived and were discharged from the hospital in stable condition after an average ICU stay. Conclusion: In this small case series, adjunctive CytoSorb hemoadsorption was associated with rapid clinical stabilization and recovery in critically ill pregnant women with COVID-19, AKI, and hyperinflammation. These promising results warrant further investigation in controlled studies to confirm the efficacy and safety of this approach.
Keywords: CytoSorb, Hemoadsorption, CRRT, ICU, AKI, COVID-19, Pregnancy
Received: 10 Jan 2025; Accepted: 13 Nov 2025.
Copyright: © 2025 Almasi, Miri, Entezarmahdi, Sabaghian, Sadeghi and Nassiri. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Amirahmad Nassiri, amirnassirimorad@gmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.